Oxford BioDynamics
Oxford BioDynamics, King's College London to Develop Biomarkers for Rheumatoid Arthritis Prevention
Oxford BioDynamics will use its EpiSwitch 3D genomics platform to develop blood-based biomarkers of disease progression and response to the drug Orencia.
In Brief This Week: Avenge Bio, Mainz Biomed, NKGen Biotech, Oxford Biodynamics, Actinium
News items for the week of Oct. 2, 2023.
Oxford BioDynamics to Raise £12.0M in Stock Placement, Offering
The company said it will use the proceeds of the transactions, which are subject to shareholder approval, to advance its EpiSwitch diagnostics platform.
Oxford BioDynamics Awarded Grant to Apply EpiSwitch to ICI Cancer Therapy Response
The two-year PACT grant will fund the application of the EpiSwitch technology to the analysis of primary and acquired ICI resistance in several clinical trials.